ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cytarabine

Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.

Drug pageCytarabine: every studyMany companies study it; this page follows only the 32 they lead. All 497 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 4, 200032 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only30 open or runningphase 3since Oct 4, 2000Oct 4, 2000none ahead
Vion Pharmaceuticalsits history only30 open or runningphase 2since Jul 19, 2006Jul 8, 2003none ahead
Antisoma Researchits history only20 open or runningphase 3since Jul 14, 2008Jul 14, 2008none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Mar 4, 2008Mar 4, 2008none ahead
Hoffmann-La Rocheits history only20 open or runningphase 2since Aug 16, 2007Aug 16, 2007none ahead
Moleculin Biotechits history only21 open or runningphase 3since Dec 5, 2024Feb 22, 2022Aug 2029phase 3 · NCT06788756
Theradexits history only20 open or runningphase 2since Oct 3, 2003Jan 27, 2003none ahead
AbbVieits history only10 open or runningphase 3since Aug 10, 2020Aug 10, 2020none ahead
Arog Pharmaceuticalsits history only10 open or runningphase 2since Oct 18, 2017Oct 18, 2017none ahead
Cornerstone Pharmaceuticalsits history only10 open or runningphase 3since Apr 12, 2018Apr 12, 2018none ahead
Kura Oncology11 open or runningphase 3since May 16, 2025May 16, 2025Nov 2031phase 3 · NCT07007312

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kura Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 16, 2025First study: phase 3 study in Leukemia, Myeloid, AcuteFirst studyNCT07007312 · 1,300 planned · United States, Australia, Belgium and more

Ahead

  1. Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07007312

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Kura Oncology leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingNov 20311,300

How it is read

Names in the registry

  • “Cytarabine”, 15 entries
  • “cytarabine”, 8 entries
  • “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
  • “Cytarabine (Ara-C)”, 1 entry
  • “Eganelisib in combination with cytarabine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.